SLRX Key Statistics, Chart & Performance
The current stock price of SLRX is 0.65 USD. In the past month the price decreased by -21.21%. In the past year, price decreased by -97.23%.
SLRX Latest News, Press Relases and Analysis
SLRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About SLRX
Company Profile
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. The company is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
Company Info
SALARIUS PHARMACEUTICALS INC
2450 Holcombe Blvd Ste J-608
Houston TEXAS 77021 US
CEO: David J. Arthur
Employees: 2
Phone: 13467720346
SALARIUS PHARMACEUTICALS INC / SLRX FAQ
Can you describe the business of SALARIUS PHARMACEUTICALS INC?
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. The company is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
What is the current price of SLRX stock?
The current stock price of SLRX is 0.65 USD. The price increased by 21.5% in the last trading session.
Does SLRX stock pay dividends?
SLRX does not pay a dividend.
What is the ChartMill rating of SALARIUS PHARMACEUTICALS INC stock?
SLRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How many employees does SALARIUS PHARMACEUTICALS INC have?
SALARIUS PHARMACEUTICALS INC (SLRX) currently has 2 employees.
What is the market capitalization of SLRX stock?
SALARIUS PHARMACEUTICALS INC (SLRX) has a market capitalization of 3.81M USD. This makes SLRX a Nano Cap stock.
SLRX Technical Analysis
SLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SLRX. SLRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SLRX Financial Highlights
Over the last trailing twelve months SLRX reported a non-GAAP Earnings per Share(EPS) of -39.18. The EPS increased by 68.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.08% | ||
| ROE | -117.81% | ||
| Debt/Equity | 0 |